THIS STORY HAS BEEN FORMATTED FOR EASY PRINTING

Research a big cost at Biogen Idec

By Michelle Fay Cortez
Bloomberg News / October 29, 2011

E-mail this article

Invalid E-mail address
Invalid E-mail address

Sending your article

Your article has been sent.

Text size +

Biogen Idec Inc.’s success with experimental drugs in the late stages of development is costing the company in other areas, driving up research spending and requiring new investments, said Paul Clancy, the company’s chief financial officer.

For more from BostonGlobe.com, sign up or log in below

To continue, please sign up or log in to BostonGlobe.com

Access the full articles and quality reporting of The Boston Globe at BostonGlobe.com

Sign up

Unlimited Access to BostonGlobe.com for 4 weeks for only 99¢.

Are you a Boston Globe home delivery subscriber?

Get FREE access as part of your print subscription.

BostonGlobe.com subscriber

Click to continue reading this article or to log in to BostonGlobe.com.

    waiting for twitterWaiting for Twitter to feed in the latest...